Literature DB >> 27177549

Progressive Neuronal Pathology and Synaptic Loss Induced by Prediabetes and Type 2 Diabetes in a Mouse Model of Alzheimer's Disease.

Juan Jose Ramos-Rodriguez1, Tara Spires-Jones2, Amy M Pooler2,3, Alfonso Maria Lechuga-Sancho4, Brian J Bacskai2, Monica Garcia-Alloza5.   

Abstract

Age remains the main risk factor for developing Alzheimer's disease (AD) although certain metabolic alterations, including prediabetes and type 2 diabetes (T2D), may also increase this risk. In order to understand this relationship, we have studied an AD-prediabetes mouse model (APP/PS1) with severe hyperinsulinemia induced by long-term high fat diet (HFD), and an AD-T2D model, generated by crossing APP/PS1 and db/db mice (APP/PS1xdb/db). In both, prediabetic and diabetic AD mice, we have analyzed underlying neuronal pathology and synaptic loss. At 26 weeks of age, when both pathologies were clearly established, we observed severe brain atrophy in APP/PS1xdb/db animals as well as cortical thinning, accompanied by increased caspase activity. Reduced senile plaque burden and elevated soluble Aβ40 and 42 levels were observed in AD-T2D mice. Further assessment revealed a significant increase of neurite curvature in prediabetic-AD mice, and this effect was worsened in AD-T2D animals. Synaptic density loss, analyzed by array tomography, revealed a synergistic effect between T2D and AD, whereas an intermediate state was observed, once more, in prediabetic-AD mice. Altogether, our data suggest that early prediabetic hyperinsulinemia may exacerbate AD pathology, and that fully established T2D clearly worsens these effects. Therefore, it is feasible that early detection of prediabetic state and strict metabolic control could slow or delay progression of AD-associated neuropathological features.

Entities:  

Keywords:  Alzheimer’s disease; Array tomography; Axonal curvature; Hyperinsulinemia; Synaptic density; Type 2 diabetes

Mesh:

Substances:

Year:  2016        PMID: 27177549     DOI: 10.1007/s12035-016-9921-3

Source DB:  PubMed          Journal:  Mol Neurobiol        ISSN: 0893-7648            Impact factor:   5.590


  45 in total

1.  Amyloid beta oligomers induce impairment of neuronal insulin receptors.

Authors:  Wei-Qin Zhao; Fernanda G De Felice; Sara Fernandez; Hui Chen; Mary P Lambert; Michael J Quon; Grant A Krafft; William L Klein
Journal:  FASEB J       Date:  2007-08-24       Impact factor: 5.191

2.  Oligomeric amyloid beta associates with postsynaptic densities and correlates with excitatory synapse loss near senile plaques.

Authors:  Robert M Koffie; Melanie Meyer-Luehmann; Tadafumi Hashimoto; Kenneth W Adams; Matthew L Mielke; Monica Garcia-Alloza; Kristina D Micheva; Stephen J Smith; M Leo Kim; Virginia M Lee; Bradley T Hyman; Tara L Spires-Jones
Journal:  Proc Natl Acad Sci U S A       Date:  2009-02-19       Impact factor: 11.205

3.  Plaque-derived oxidative stress mediates distorted neurite trajectories in the Alzheimer mouse model.

Authors:  Monica Garcia-Alloza; Sarah A Dodwell; Melanie Meyer-Luehmann; Bradley T Hyman; Brian J Bacskai
Journal:  J Neuropathol Exp Neurol       Date:  2006-11       Impact factor: 3.685

4.  Curcumin labels amyloid pathology in vivo, disrupts existing plaques, and partially restores distorted neurites in an Alzheimer mouse model.

Authors:  M Garcia-Alloza; L A Borrelli; A Rozkalne; B T Hyman; B J Bacskai
Journal:  J Neurochem       Date:  2007-04-30       Impact factor: 5.372

5.  Diabetes mellitus and risk of Alzheimer disease and decline in cognitive function.

Authors:  Zoe Arvanitakis; Robert S Wilson; Julia L Bienias; Denis A Evans; David A Bennett
Journal:  Arch Neurol       Date:  2004-05

6.  Defective insulin signaling pathway and increased glycogen synthase kinase-3 activity in the brain of diabetic mice: parallels with Alzheimer's disease and correction by insulin.

Authors:  C G Jolivalt; C A Lee; K K Beiswenger; J L Smith; M Orlov; M A Torrance; E Masliah
Journal:  J Neurosci Res       Date:  2008-11-15       Impact factor: 4.164

7.  Perforant path synaptic loss correlates with cognitive impairment and Alzheimer's disease in the oldest-old.

Authors:  John L Robinson; Laura Molina-Porcel; Maria M Corrada; Kevin Raible; Edward B Lee; Virginia M-Y Lee; Claudia H Kawas; John Q Trojanowski
Journal:  Brain       Date:  2014-07-09       Impact factor: 13.501

8.  Long-term central pathology and cognitive impairment are exacerbated in a mixed model of Alzheimer's disease and type 2 diabetes.

Authors:  Carmen Infante-Garcia; Juan Jose Ramos-Rodriguez; Lucia Galindo-Gonzalez; Monica Garcia-Alloza
Journal:  Psychoneuroendocrinology       Date:  2015-12-03       Impact factor: 4.905

9.  Relation of diabetes to mild cognitive impairment.

Authors:  José A Luchsinger; Christiane Reitz; Bindu Patel; Ming-Xin Tang; Jennifer J Manly; Richard Mayeux
Journal:  Arch Neurol       Date:  2007-04

10.  Insulin resistance and risk of ischemic stroke among nondiabetic individuals from the northern Manhattan study.

Authors:  Tatjana Rundek; Hannah Gardener; Qiang Xu; Ronald B Goldberg; Clinton B Wright; Bernadette Boden-Albala; Norbelina Disla; Myunghee C Paik; Mitchell S V Elkind; Ralph L Sacco
Journal:  Arch Neurol       Date:  2010-10
View more
  21 in total

Review 1.  Is Alzheimer's Disease Risk Modifiable?

Authors:  Alberto Serrano-Pozo; John H Growdon
Journal:  J Alzheimers Dis       Date:  2019       Impact factor: 4.472

Review 2.  The effects of insulin and insulin-like growth factor I on amyloid precursor protein phosphorylation in in vitro and in vivo models of Alzheimer's disease.

Authors:  Bhumsoo Kim; Sarah E Elzinga; Rosemary E Henn; Lisa M McGinley; Eva L Feldman
Journal:  Neurobiol Dis       Date:  2019-07-23       Impact factor: 5.996

Review 3.  Metabolic, inflammatory, and microvascular determinants of white matter disease and cognitive decline.

Authors:  Maggie Wang; Jennifer E Norman; Vivek J Srinivasan; John C Rutledge
Journal:  Am J Neurodegener Dis       Date:  2016-11-30

4.  Cognitive Impairment and Brain and Peripheral Alterations in a Murine Model of Intraventricular Hemorrhage in the Preterm Newborn.

Authors:  Antonio Segado-Arenas; Carmen Infante-Garcia; Isabel Benavente-Fernandez; Daniel Sanchez-Sotano; Juan Jose Ramos-Rodriguez; Almudena Alonso-Ojembarrena; Simon Lubian-Lopez; Monica Garcia-Alloza
Journal:  Mol Neurobiol       Date:  2017-07-28       Impact factor: 5.590

Review 5.  Insulin resistance and impaired lipid metabolism as a potential link between diabetes and Alzheimer's disease.

Authors:  Joshua A Kulas; Thaddeus K Weigel; Heather A Ferris
Journal:  Drug Dev Res       Date:  2020-02-05       Impact factor: 4.360

6.  Antidiabetic Polypill Improves Central Pathology and Cognitive Impairment in a Mixed Model of Alzheimer's Disease and Type 2 Diabetes.

Authors:  Carmen Infante-Garcia; Juan Jose Ramos-Rodriguez; Carmen Hierro-Bujalance; Esperanza Ortegon; Eleanor Pickett; Rosemary Jackson; Fernando Hernandez-Pacho; Tara Spires-Jones; Monica Garcia-Alloza
Journal:  Mol Neurobiol       Date:  2017-12-09       Impact factor: 5.590

7.  Central insulin dysregulation and energy dyshomeostasis in two mouse models of Alzheimer's disease.

Authors:  Ramon Velazquez; An Tran; Egide Ishimwe; Larry Denner; Nikhil Dave; Salvatore Oddo; Kelly T Dineley
Journal:  Neurobiol Aging       Date:  2017-06-17       Impact factor: 4.673

8.  Mechanisms Associated with Type 2 Diabetes as a Risk Factor for Alzheimer-Related Pathology.

Authors:  Men Su; Kambiz Naderi; Nathalie Samson; Ihsen Youssef; Livia Fülöp; Zsolt Bozso; Serge Laroche; Benoit Delatour; Sabrina Davis
Journal:  Mol Neurobiol       Date:  2019-01-25       Impact factor: 5.590

Review 9.  Dysmetabolism and Neurodegeneration: Trick or Treat?

Authors:  Adriana M Capucho; Ana Chegão; Fátima O Martins; Hugo Vicente Miranda; Sílvia V Conde
Journal:  Nutrients       Date:  2022-03-29       Impact factor: 5.717

Review 10.  Beyond the neuron-cellular interactions early in Alzheimer disease pathogenesis.

Authors:  Christopher M Henstridge; Bradley T Hyman; Tara L Spires-Jones
Journal:  Nat Rev Neurosci       Date:  2019-02       Impact factor: 34.870

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.